세계의 와파린 나트륨(CAS 129-06-6) 시장 규모 : 유형별, 용도별, 지역 범위별 및 예측

Warfarin Sodium (CAS 129-06-6) Market Size And Forecast

Warfarin Sodium (CAS 129-06-6) Market size was valued at USD 197.69 Billion in 2024 and is projected to reach USD 283.3 Billion by 2032, growing at a CAGR of 4.60% from 2026 to 2032.

The increasing preference for warfarin sodium for the prevention of blood clotting has created the demand for this product in healthcare, thereby driving the global market growth. The Global Warfarin Sodium (CAS 129-06-6) Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Warfarin Sodium (CAS 129-06-6) Market is estimated to grow at a CAGR of 4.60% & reach US$ 283.3 Bn by the end of 2032

Global Warfarin Sodium (CAS 129-06-6) Market Definition

Warfarin Sodium is the sodium salt form of warfarin, with anticoagulant activity. CAS 129-06-6 is a unique numerical identifier of warfarin sodium assigned by the Chemical Abstracts Service. It is commonly used to treat blood clots such as deep vein thrombosis and pulmonary embolism, and to prevent stroke in people who have atrial fibrillation, valvular heart disease, or artificial heart valves. Warfarin Sodium is categorized into three types: 1 mg/Tablet, 2.5 mg/Tablet, and 5 mg/Tablet.

It is generally taken by mouth, but can also be used by injection into a vein. Warfarin sodium inhibits vitamin K and vitamin K epoxide reductases, thereby obstructing the cyclic interconversion of vitamin K epoxide to its diminished form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of glutamate resting on the N-terminal regions of vitamin K-dependent proteins. The most common side effect is bleeding and less common side effects include areas of tissue damage and purple toes syndrome.

Global Warfarin Sodium (CAS 129-06-6) Market Overview

Thus, the increasing preference for warfarin sodium for the prevention of blood clotting has created the demand for this product in healthcare, thereby driving the global market growth. However, the several side effects of warfarin sodium such as red or brown urine, black or bloody stool, severe headache or stomach pain, joint pain, vomiting, and coughing up blood are hampering the global market growth. Overdose of warfarin sodium also leads to severe blooding or heavier than normal menstrual bleeding, which is also expected to restrict the market growth.

Global Warfarin Sodium (CAS 129-06-6) Market Segmentation Analysis

The Global Warfarin Sodium (CAS 129-06-6) Market Is Segmented On The Basis Of Type, Application, And Geography.

Warfarin Sodium (CAS 129-06-6) Market, By Type

1mg/Tablet

• 2.5mg/Tablet

5mg/Tablet

Based on Type, the market is segmented into 1mg/Tablet, 2.5mg/Tablet, and 5mg/Tablet. Warfarin, an anticoagulant works by preventing the formation of harmful blood clots. Although it does not dissolve the existing blood clots, it prevents them from growing larger and causing blockages in the blood vessels. It also has a common side effect of Bleeding. Hence it is always advised to consume Warfarin in small amounts. Hence 1mg/Tablets are consumed more and these factors are expected to boost demand for 1mg/Tablets and further propel market growth.

Warfarin Sodium (CAS 129-06-6) Market, By Application

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on Application, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital pharmacies usually stock a larger variety of medications, including more specialized and investigational medications, than would be feasible in the community setting. Pharmacists in hotels are more trained and equipped. Warfarin can interact with several medicines hence expert advice is always needed. These factors are expected to boost demand and further propel market growth.

Warfarin Sodium (CAS 129-06-6) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, the Global Warfarin Sodium (CAS 129-06-6) Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The Europe market is said to be the Fastest Growing Market for Warfarin Sodium (CAS 129-06-6) because there is the highest awareness of deep vein thrombosis and pulmonary embolism and Warfarin is used to prevent stroke prevention, deep vein thrombosis, and pulmonary embolism. The Asia-Pacific place is predicted to develop because of a lack of awareness right now. With the increase in awareness the market will grow too.

Key Players

The "Global Warfarin Sodium (CAS 129-06-6) Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Qilu Pharma, Sine Pharma, Jialin Pharma, Fuda Pharma, Zhongjie Pharma, Amneal Pharma, TEVA, Mylan, and Cipla.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• Warfarin Sodium (CAS 129-06-6) Market Key Developments And Mergers
• In 2021, Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership.
• IN 2018, Qilu ranked top 10 of the Chinese Pharmaceutical Industry in 4 consecutive times.
• Cipla was awarded Company of the year 2021 buy the Business Standard.
• KEY COMPANIES PROFILED
• Qilu Pharma, Sine Pharma, Jialin Pharma, Fuda Pharma, Zhongjie Pharma, Amneal Pharma, TEVA, Mylan, and Cipla.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET, BY TYPE

• 5.1 Overview
• 5.21mg/Tablet
• 5.3 2.5mg/Tablet
• 5.4 5mg/Tablet

6 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Hospital Pharmacies
• 6.3 Retail Pharmacies
• 6.4 Online Pharmacies

7 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL WARFARIN SODIUM (CAS129-06-6) MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Qilu Pharma
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Sine Pharma
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Jialin Pharma
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Fuda Pharma
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Zhongjie Pharma
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Amneal Pharma
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 TEVA
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Mylan
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Cipla
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments

10 Appendix

• 10.1 Related Research